| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hypoplastic Left Heart Syndrome | 19 | 2025 | 271 | 5.220 |
Why?
|
| Heart Defects, Congenital | 37 | 2025 | 1874 | 4.880 |
Why?
|
| Marfan Syndrome | 16 | 2025 | 144 | 4.650 |
Why?
|
| Loeys-Dietz Syndrome | 12 | 2025 | 42 | 4.300 |
Why?
|
| Echocardiography | 23 | 2025 | 1111 | 3.220 |
Why?
|
| Ultrasonography, Prenatal | 22 | 2025 | 985 | 3.160 |
Why?
|
| Fetal Heart | 13 | 2025 | 129 | 3.030 |
Why?
|
| Turner Syndrome | 7 | 2022 | 46 | 2.340 |
Why?
|
| Transposition of Great Vessels | 6 | 2024 | 133 | 2.170 |
Why?
|
| Ehlers-Danlos Syndrome | 6 | 2025 | 53 | 2.020 |
Why?
|
| Heterotaxy Syndrome | 4 | 2024 | 61 | 1.820 |
Why?
|
| Arteries | 6 | 2024 | 223 | 1.660 |
Why?
|
| Skin Diseases, Genetic | 5 | 2023 | 15 | 1.600 |
Why?
|
| Joint Instability | 5 | 2023 | 54 | 1.550 |
Why?
|
| Aortic Valve | 10 | 2024 | 454 | 1.510 |
Why?
|
| Aorta | 10 | 2024 | 555 | 1.490 |
Why?
|
| Vascular Malformations | 5 | 2023 | 104 | 1.440 |
Why?
|
| Aortic Aneurysm, Thoracic | 11 | 2025 | 678 | 1.420 |
Why?
|
| Pregnancy | 35 | 2025 | 7515 | 1.410 |
Why?
|
| Retrospective Studies | 62 | 2025 | 17456 | 1.370 |
Why?
|
| Aorta, Thoracic | 10 | 2025 | 536 | 1.340 |
Why?
|
| Hospital Mortality | 13 | 2024 | 1083 | 1.330 |
Why?
|
| Scimitar Syndrome | 2 | 2021 | 52 | 1.300 |
Why?
|
| Female | 113 | 2025 | 71584 | 1.280 |
Why?
|
| Heart Septal Defects, Atrial | 4 | 2025 | 127 | 1.240 |
Why?
|
| Heart Ventricles | 13 | 2024 | 799 | 1.230 |
Why?
|
| Humans | 162 | 2025 | 133849 | 1.230 |
Why?
|
| Mitral Valve Insufficiency | 3 | 2025 | 174 | 1.220 |
Why?
|
| Infant Mortality | 8 | 2024 | 180 | 1.210 |
Why?
|
| Aortic Diseases | 5 | 2025 | 202 | 1.200 |
Why?
|
| Cardiac Catheterization | 7 | 2025 | 662 | 1.130 |
Why?
|
| Heart Valve Diseases | 8 | 2024 | 181 | 1.130 |
Why?
|
| Infant, Newborn | 37 | 2024 | 8576 | 1.090 |
Why?
|
| Aortic Stenosis, Supravalvular | 2 | 2024 | 21 | 1.090 |
Why?
|
| Heart Transplantation | 8 | 2023 | 894 | 1.080 |
Why?
|
| Premature Birth | 2 | 2022 | 417 | 1.060 |
Why?
|
| Child | 59 | 2025 | 25712 | 1.050 |
Why?
|
| Mitral Valve | 4 | 2024 | 268 | 1.040 |
Why?
|
| Cardiac Surgical Procedures | 9 | 2024 | 1159 | 1.010 |
Why?
|
| Atrial Septum | 1 | 2025 | 19 | 0.970 |
Why?
|
| Infant | 43 | 2024 | 13135 | 0.950 |
Why?
|
| Gestational Age | 10 | 2025 | 1217 | 0.920 |
Why?
|
| Registries | 17 | 2024 | 1561 | 0.910 |
Why?
|
| Adolescent | 48 | 2025 | 20517 | 0.900 |
Why?
|
| Cor Triatriatum | 1 | 2024 | 10 | 0.880 |
Why?
|
| Prenatal Diagnosis | 6 | 2023 | 627 | 0.880 |
Why?
|
| Male | 83 | 2025 | 65815 | 0.880 |
Why?
|
| Williams Syndrome | 1 | 2024 | 42 | 0.870 |
Why?
|
| Ventricular Function, Left | 4 | 2024 | 541 | 0.870 |
Why?
|
| Tetralogy of Fallot | 6 | 2021 | 165 | 0.860 |
Why?
|
| Aortic Valve Stenosis | 3 | 2025 | 346 | 0.860 |
Why?
|
| Child, Preschool | 37 | 2025 | 14776 | 0.840 |
Why?
|
| Aortic Coarctation | 2 | 2021 | 110 | 0.820 |
Why?
|
| Stroke Volume | 3 | 2024 | 530 | 0.810 |
Why?
|
| Pregnancy Complications | 5 | 2023 | 547 | 0.810 |
Why?
|
| Pulmonary Valve | 2 | 2021 | 96 | 0.730 |
Why?
|
| Ventricular Dysfunction, Left | 5 | 2024 | 381 | 0.720 |
Why?
|
| DiGeorge Syndrome | 1 | 2021 | 82 | 0.720 |
Why?
|
| Risk Factors | 29 | 2025 | 11077 | 0.720 |
Why?
|
| Patient Discharge | 1 | 2025 | 518 | 0.710 |
Why?
|
| Connective Tissue Diseases | 4 | 2016 | 33 | 0.710 |
Why?
|
| Adult | 45 | 2025 | 31925 | 0.700 |
Why?
|
| Urinary Bladder Diseases | 1 | 2020 | 34 | 0.690 |
Why?
|
| Hospitalization | 5 | 2024 | 1884 | 0.680 |
Why?
|
| Down Syndrome | 3 | 2020 | 230 | 0.670 |
Why?
|
| Hospitals | 2 | 2021 | 429 | 0.670 |
Why?
|
| Pregnancy Complications, Cardiovascular | 2 | 2018 | 105 | 0.670 |
Why?
|
| Pulmonary Veins | 2 | 2021 | 166 | 0.670 |
Why?
|
| Abnormalities, Multiple | 4 | 2019 | 977 | 0.670 |
Why?
|
| Mutation | 13 | 2024 | 6289 | 0.650 |
Why?
|
| Texas | 14 | 2024 | 3684 | 0.640 |
Why?
|
| Ebstein Anomaly | 4 | 2021 | 29 | 0.640 |
Why?
|
| Life Support Care | 1 | 2019 | 48 | 0.630 |
Why?
|
| Mitral Valve Annuloplasty | 1 | 2019 | 17 | 0.630 |
Why?
|
| United States | 21 | 2025 | 11682 | 0.610 |
Why?
|
| Magnetic Resonance Imaging, Cine | 5 | 2024 | 161 | 0.600 |
Why?
|
| Vascular Resistance | 2 | 2018 | 194 | 0.600 |
Why?
|
| Receptors, Transforming Growth Factor beta | 2 | 2016 | 106 | 0.600 |
Why?
|
| Trypanosoma cruzi | 10 | 1998 | 251 | 0.580 |
Why?
|
| Heart Atria | 4 | 2020 | 333 | 0.580 |
Why?
|
| Attitude to Health | 1 | 2019 | 261 | 0.570 |
Why?
|
| Adenylyl Cyclases | 13 | 1999 | 89 | 0.570 |
Why?
|
| Disease Progression | 1 | 2024 | 2239 | 0.570 |
Why?
|
| Influenza, Human | 1 | 2024 | 691 | 0.570 |
Why?
|
| Meningomyelocele | 1 | 2021 | 255 | 0.560 |
Why?
|
| Phenotype | 14 | 2025 | 4532 | 0.540 |
Why?
|
| Aortic Rupture | 2 | 2016 | 120 | 0.540 |
Why?
|
| Consensus | 2 | 2019 | 739 | 0.520 |
Why?
|
| Family | 1 | 2019 | 588 | 0.510 |
Why?
|
| Fetus | 6 | 2022 | 599 | 0.510 |
Why?
|
| Young Adult | 27 | 2025 | 9885 | 0.500 |
Why?
|
| Aortic Aneurysm | 3 | 2017 | 234 | 0.480 |
Why?
|
| Patient Care Team | 1 | 2019 | 573 | 0.470 |
Why?
|
| Cerebrovascular Circulation | 1 | 2018 | 473 | 0.470 |
Why?
|
| Time Factors | 13 | 2025 | 6584 | 0.470 |
Why?
|
| Oxygen | 1 | 2018 | 577 | 0.460 |
Why?
|
| Pulmonary Valve Stenosis | 3 | 2024 | 40 | 0.460 |
Why?
|
| Cesarean Section | 1 | 2018 | 400 | 0.460 |
Why?
|
| Vascular Surgical Procedures | 2 | 2019 | 559 | 0.460 |
Why?
|
| Tricuspid Valve | 3 | 2020 | 63 | 0.460 |
Why?
|
| Mitral Valve Prolapse | 2 | 2024 | 31 | 0.450 |
Why?
|
| Calcium Channels | 6 | 2001 | 165 | 0.450 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2019 | 452 | 0.450 |
Why?
|
| Treatment Outcome | 22 | 2025 | 13011 | 0.440 |
Why?
|
| Databases, Factual | 6 | 2022 | 1240 | 0.440 |
Why?
|
| Collagen Type III | 3 | 2025 | 26 | 0.440 |
Why?
|
| Fetal Therapies | 3 | 2020 | 83 | 0.440 |
Why?
|
| Myocardium | 10 | 2014 | 1046 | 0.440 |
Why?
|
| Cardiomyopathies | 4 | 2024 | 514 | 0.410 |
Why?
|
| Cohort Studies | 11 | 2024 | 5173 | 0.400 |
Why?
|
| Predictive Value of Tests | 7 | 2024 | 2292 | 0.400 |
Why?
|
| Chagas Cardiomyopathy | 9 | 1994 | 53 | 0.400 |
Why?
|
| Receptors, Adrenergic, beta | 7 | 1996 | 65 | 0.400 |
Why?
|
| Smad3 Protein | 2 | 2024 | 59 | 0.400 |
Why?
|
| Vertebral Artery | 2 | 2014 | 24 | 0.390 |
Why?
|
| Length of Stay | 5 | 2024 | 1380 | 0.390 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 6 | 2001 | 392 | 0.390 |
Why?
|
| Chagas Disease | 8 | 1996 | 309 | 0.380 |
Why?
|
| Calcium | 9 | 2001 | 1146 | 0.380 |
Why?
|
| Thoracic Surgery | 1 | 2013 | 162 | 0.370 |
Why?
|
| Verapamil | 5 | 1996 | 58 | 0.370 |
Why?
|
| Tricuspid Valve Insufficiency | 3 | 2021 | 64 | 0.360 |
Why?
|
| Risk Assessment | 8 | 2025 | 3691 | 0.350 |
Why?
|
| DNA | 2 | 2020 | 1675 | 0.350 |
Why?
|
| Endothelium, Vascular | 8 | 2019 | 522 | 0.350 |
Why?
|
| Pedigree | 2 | 2024 | 1694 | 0.350 |
Why?
|
| Wolff-Parkinson-White Syndrome | 2 | 2022 | 72 | 0.340 |
Why?
|
| Echocardiography, Doppler, Color | 3 | 2021 | 113 | 0.330 |
Why?
|
| Umbilical Arteries | 2 | 2022 | 98 | 0.330 |
Why?
|
| Dilatation, Pathologic | 3 | 2021 | 97 | 0.330 |
Why?
|
| GTP-Binding Proteins | 9 | 1996 | 188 | 0.320 |
Why?
|
| Balloon Valvuloplasty | 2 | 2020 | 25 | 0.320 |
Why?
|
| Pregnancy Outcome | 6 | 2021 | 624 | 0.310 |
Why?
|
| Age Factors | 8 | 2024 | 2975 | 0.300 |
Why?
|
| Infant, Newborn, Diseases | 2 | 2022 | 180 | 0.300 |
Why?
|
| Inpatients | 1 | 2013 | 535 | 0.300 |
Why?
|
| Live Birth | 4 | 2021 | 70 | 0.300 |
Why?
|
| Magnetic Resonance Angiography | 4 | 2019 | 168 | 0.290 |
Why?
|
| Ventricular Dysfunction, Right | 2 | 2021 | 79 | 0.280 |
Why?
|
| Cardiology | 3 | 2020 | 520 | 0.280 |
Why?
|
| Tachycardia, Supraventricular | 2 | 2022 | 111 | 0.280 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2025 | 3476 | 0.270 |
Why?
|
| Genetic Testing | 3 | 2024 | 1093 | 0.270 |
Why?
|
| Vascular Stiffness | 3 | 2019 | 80 | 0.260 |
Why?
|
| Fetal Diseases | 4 | 2024 | 462 | 0.260 |
Why?
|
| Genotype | 6 | 2024 | 2807 | 0.260 |
Why?
|
| Fibrillin-1 | 5 | 2025 | 61 | 0.250 |
Why?
|
| Postoperative Complications | 7 | 2022 | 3226 | 0.250 |
Why?
|
| Calcium Channel Blockers | 2 | 1996 | 117 | 0.250 |
Why?
|
| Filamins | 2 | 2017 | 27 | 0.250 |
Why?
|
| Heart Septal Defects, Ventricular | 2 | 2020 | 134 | 0.250 |
Why?
|
| Severity of Illness Index | 5 | 2025 | 3063 | 0.240 |
Why?
|
| Ultrasonography, Doppler | 3 | 2021 | 198 | 0.240 |
Why?
|
| Transforming Growth Factor beta3 | 1 | 2025 | 9 | 0.240 |
Why?
|
| Cause of Death | 2 | 2018 | 502 | 0.230 |
Why?
|
| Pilot Projects | 5 | 2023 | 1485 | 0.230 |
Why?
|
| Jaundice, Neonatal | 1 | 2004 | 10 | 0.230 |
Why?
|
| Parathyroid Hormone | 2 | 2008 | 78 | 0.220 |
Why?
|
| Losartan | 2 | 2020 | 36 | 0.220 |
Why?
|
| Coronary Vessels | 3 | 2019 | 566 | 0.220 |
Why?
|
| Smad4 Protein | 1 | 2024 | 58 | 0.220 |
Why?
|
| Incidence | 7 | 2017 | 3393 | 0.220 |
Why?
|
| Health Information Systems | 1 | 2024 | 35 | 0.220 |
Why?
|
| Elastin | 1 | 2024 | 31 | 0.220 |
Why?
|
| Kaplan-Meier Estimate | 5 | 2018 | 1139 | 0.210 |
Why?
|
| Animals | 35 | 2024 | 36363 | 0.210 |
Why?
|
| Fetal Death | 2 | 2021 | 121 | 0.210 |
Why?
|
| Pulmonary Atresia | 2 | 2024 | 48 | 0.210 |
Why?
|
| Prospective Studies | 8 | 2022 | 6655 | 0.210 |
Why?
|
| Prevalence | 5 | 2024 | 2654 | 0.210 |
Why?
|
| Mechanotransduction, Cellular | 1 | 2014 | 74 | 0.210 |
Why?
|
| Multicenter Studies as Topic | 1 | 2024 | 290 | 0.210 |
Why?
|
| Propensity Score | 1 | 2024 | 258 | 0.200 |
Why?
|
| Immunization | 1 | 2004 | 315 | 0.200 |
Why?
|
| RNA Splicing | 1 | 2024 | 250 | 0.200 |
Why?
|
| Supreme Court Decisions | 1 | 2022 | 17 | 0.200 |
Why?
|
| Fibrillins | 4 | 2022 | 31 | 0.200 |
Why?
|
| Palliative Care | 4 | 2020 | 461 | 0.200 |
Why?
|
| Disease Management | 2 | 2024 | 560 | 0.200 |
Why?
|
| Respiration, Artificial | 2 | 2024 | 497 | 0.190 |
Why?
|
| DNA Copy Number Variations | 2 | 2018 | 1022 | 0.190 |
Why?
|
| American Heart Association | 1 | 2024 | 328 | 0.190 |
Why?
|
| Cardiomyopathy, Dilated | 1 | 2014 | 217 | 0.190 |
Why?
|
| Ectopia Lentis | 1 | 2022 | 12 | 0.190 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2024 | 577 | 0.190 |
Why?
|
| Middle Aged | 15 | 2025 | 29371 | 0.190 |
Why?
|
| Maternal-Fetal Exchange | 2 | 2020 | 85 | 0.190 |
Why?
|
| Sex Factors | 4 | 2020 | 1384 | 0.180 |
Why?
|
| Chromosome Deletion | 2 | 2021 | 664 | 0.180 |
Why?
|
| Obesity | 1 | 2013 | 2410 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2018 | 830 | 0.180 |
Why?
|
| Medical Illustration | 1 | 2021 | 19 | 0.180 |
Why?
|
| Ecchymosis | 1 | 2020 | 12 | 0.180 |
Why?
|
| Ataxia | 1 | 2022 | 177 | 0.180 |
Why?
|
| Peritoneal Cavity | 1 | 2020 | 20 | 0.180 |
Why?
|
| Rupture, Spontaneous | 1 | 2020 | 51 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 3843 | 0.180 |
Why?
|
| Multivariate Analysis | 3 | 2019 | 1489 | 0.170 |
Why?
|
| Hospital Charges | 1 | 2021 | 63 | 0.170 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2020 | 5 | 0.170 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 5505 | 0.170 |
Why?
|
| Receptors, Adrenergic, beta-1 | 1 | 2020 | 14 | 0.170 |
Why?
|
| Hernia, Inguinal | 1 | 2020 | 43 | 0.170 |
Why?
|
| Vena Cava, Inferior | 1 | 2021 | 104 | 0.170 |
Why?
|
| Pulmonary Valve Insufficiency | 1 | 2020 | 42 | 0.170 |
Why?
|
| Atenolol | 1 | 2020 | 43 | 0.170 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 214 | 0.170 |
Why?
|
| Intersectoral Collaboration | 1 | 2020 | 21 | 0.170 |
Why?
|
| Ductus Arteriosus | 1 | 2020 | 62 | 0.170 |
Why?
|
| Herniorrhaphy | 1 | 2020 | 85 | 0.170 |
Why?
|
| Health Services Misuse | 1 | 2000 | 28 | 0.170 |
Why?
|
| Neurovascular Coupling | 1 | 2019 | 10 | 0.160 |
Why?
|
| Stakeholder Participation | 1 | 2020 | 32 | 0.160 |
Why?
|
| Bioethical Issues | 1 | 2019 | 23 | 0.160 |
Why?
|
| Outpatient Clinics, Hospital | 1 | 2000 | 77 | 0.160 |
Why?
|
| Hospitals, Urban | 1 | 2000 | 99 | 0.160 |
Why?
|
| Treatment Refusal | 1 | 2020 | 80 | 0.160 |
Why?
|
| Myocarditis | 1 | 2021 | 137 | 0.160 |
Why?
|
| Abdominal Injuries | 1 | 2020 | 117 | 0.160 |
Why?
|
| Isolated Noncompaction of the Ventricular Myocardium | 1 | 2019 | 44 | 0.160 |
Why?
|
| Critical Illness | 2 | 2022 | 622 | 0.160 |
Why?
|
| Thulium | 1 | 2019 | 6 | 0.160 |
Why?
|
| Coronary Occlusion | 1 | 2019 | 29 | 0.160 |
Why?
|
| Defibrillators, Implantable | 1 | 2022 | 196 | 0.160 |
Why?
|
| Clinical Decision-Making | 2 | 2018 | 292 | 0.160 |
Why?
|
| Electrocardiography | 4 | 2019 | 1006 | 0.160 |
Why?
|
| Proton-Translocating ATPases | 1 | 1999 | 18 | 0.160 |
Why?
|
| Accidental Falls | 1 | 2020 | 126 | 0.150 |
Why?
|
| Lymphatic Vessels | 1 | 2019 | 37 | 0.150 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2020 | 122 | 0.150 |
Why?
|
| Signal Transduction | 7 | 2016 | 4896 | 0.150 |
Why?
|
| Diastole | 2 | 2020 | 185 | 0.150 |
Why?
|
| Vacuolar Proton-Translocating ATPases | 1 | 1999 | 23 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-3 | 1 | 2018 | 4 | 0.150 |
Why?
|
| Prognosis | 5 | 2021 | 5070 | 0.150 |
Why?
|
| Longevity | 1 | 2020 | 158 | 0.150 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2018 | 2196 | 0.150 |
Why?
|
| Case-Control Studies | 3 | 2018 | 3638 | 0.150 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2018 | 40 | 0.150 |
Why?
|
| Arrhythmias, Cardiac | 2 | 2024 | 478 | 0.150 |
Why?
|
| Lymphatic Abnormalities | 1 | 2019 | 36 | 0.150 |
Why?
|
| Coronary Circulation | 1 | 2019 | 219 | 0.150 |
Why?
|
| Perinatal Care | 1 | 2019 | 68 | 0.150 |
Why?
|
| Truncus Arteriosus, Persistent | 1 | 2018 | 18 | 0.150 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2020 | 319 | 0.150 |
Why?
|
| Clinical Competence | 3 | 2017 | 1066 | 0.150 |
Why?
|
| Proportional Hazards Models | 3 | 2016 | 1482 | 0.150 |
Why?
|
| Pulsatile Flow | 1 | 2018 | 128 | 0.150 |
Why?
|
| Abdominal Pain | 1 | 2020 | 313 | 0.150 |
Why?
|
| Uterine Artery | 1 | 2018 | 29 | 0.150 |
Why?
|
| Vasodilator Agents | 3 | 2016 | 213 | 0.140 |
Why?
|
| Tracheostomy | 1 | 2020 | 201 | 0.140 |
Why?
|
| Mydriasis | 1 | 2018 | 8 | 0.140 |
Why?
|
| Genetic Variation | 1 | 2025 | 1621 | 0.140 |
Why?
|
| Neck | 1 | 2019 | 143 | 0.140 |
Why?
|
| Eye Diseases, Hereditary | 1 | 2018 | 33 | 0.140 |
Why?
|
| Heart-Assist Devices | 2 | 2019 | 1093 | 0.140 |
Why?
|
| Stents | 3 | 2019 | 877 | 0.140 |
Why?
|
| Esophageal Atresia | 1 | 2018 | 52 | 0.140 |
Why?
|
| Tracheoesophageal Fistula | 1 | 2018 | 48 | 0.140 |
Why?
|
| Fluorescent Dyes | 1 | 1999 | 270 | 0.140 |
Why?
|
| Imidazoles | 1 | 1999 | 217 | 0.140 |
Why?
|
| Heart | 3 | 2017 | 749 | 0.140 |
Why?
|
| Ventricular Function, Right | 2 | 2021 | 116 | 0.140 |
Why?
|
| Seizures | 1 | 2022 | 889 | 0.140 |
Why?
|
| Walking | 1 | 2019 | 235 | 0.140 |
Why?
|
| Pyridines | 1 | 1999 | 247 | 0.140 |
Why?
|
| Patient Participation | 1 | 2020 | 234 | 0.140 |
Why?
|
| Practice Guidelines as Topic | 1 | 2024 | 1334 | 0.140 |
Why?
|
| Pectus Carinatum | 1 | 2017 | 5 | 0.140 |
Why?
|
| Pacemaker, Artificial | 2 | 2017 | 177 | 0.140 |
Why?
|
| Transcription Factors | 2 | 2024 | 2703 | 0.130 |
Why?
|
| Reproducibility of Results | 4 | 2023 | 3050 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 1 | 2019 | 205 | 0.130 |
Why?
|
| Health Expenditures | 1 | 2018 | 116 | 0.130 |
Why?
|
| Cholera Toxin | 6 | 1994 | 52 | 0.130 |
Why?
|
| Enterocolitis, Necrotizing | 1 | 2020 | 248 | 0.130 |
Why?
|
| Pericardium | 1 | 2017 | 85 | 0.130 |
Why?
|
| Arterio-Arterial Fistula | 1 | 2016 | 9 | 0.130 |
Why?
|
| Heart Conduction System | 1 | 2017 | 149 | 0.130 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2019 | 342 | 0.130 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2017 | 54 | 0.130 |
Why?
|
| Cyclic AMP | 3 | 1992 | 262 | 0.130 |
Why?
|
| Extracellular Matrix | 2 | 2014 | 249 | 0.130 |
Why?
|
| Myocardial Contraction | 2 | 2017 | 271 | 0.130 |
Why?
|
| Lung | 2 | 2021 | 1557 | 0.130 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2016 | 7 | 0.130 |
Why?
|
| Heart Neoplasms | 1 | 2017 | 106 | 0.130 |
Why?
|
| Teratoma | 1 | 2017 | 130 | 0.130 |
Why?
|
| Antifungal Agents | 2 | 2000 | 309 | 0.130 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2016 | 10 | 0.130 |
Why?
|
| Chromosomes, Human, Pair 20 | 1 | 2016 | 34 | 0.130 |
Why?
|
| Hemodynamics | 2 | 2017 | 868 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2020 | 927 | 0.120 |
Why?
|
| Pediatrics | 3 | 2017 | 1216 | 0.120 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2015 | 10 | 0.120 |
Why?
|
| Ductus Arteriosus, Patent | 1 | 2018 | 148 | 0.120 |
Why?
|
| Physicians | 1 | 2022 | 630 | 0.120 |
Why?
|
| Enzyme Inhibitors | 1 | 1999 | 607 | 0.120 |
Why?
|
| Alprostadil | 1 | 2015 | 26 | 0.120 |
Why?
|
| Hypertension | 2 | 2016 | 1391 | 0.120 |
Why?
|
| Moyamoya Disease | 1 | 2016 | 42 | 0.120 |
Why?
|
| Esophageal Achalasia | 1 | 2016 | 44 | 0.120 |
Why?
|
| Actins | 1 | 2018 | 352 | 0.120 |
Why?
|
| Program Evaluation | 1 | 2017 | 455 | 0.120 |
Why?
|
| Atrioventricular Block | 1 | 2016 | 40 | 0.120 |
Why?
|
| Inositol 1,4,5-Trisphosphate Receptors | 6 | 2001 | 34 | 0.120 |
Why?
|
| Aortography | 1 | 2016 | 192 | 0.120 |
Why?
|
| Hypertension, Pulmonary | 2 | 2017 | 467 | 0.120 |
Why?
|
| Gene Expression Regulation | 3 | 2020 | 2656 | 0.120 |
Why?
|
| Pneumocystis | 1 | 1994 | 12 | 0.110 |
Why?
|
| International Cooperation | 1 | 2015 | 167 | 0.110 |
Why?
|
| Respiratory Insufficiency | 1 | 2017 | 239 | 0.110 |
Why?
|
| Prostheses and Implants | 1 | 2016 | 161 | 0.110 |
Why?
|
| Attitude of Health Personnel | 1 | 2020 | 711 | 0.110 |
Why?
|
| Fracture Fixation | 1 | 2014 | 28 | 0.110 |
Why?
|
| Virulence Factors, Bordetella | 5 | 1994 | 24 | 0.110 |
Why?
|
| Hyperoxia | 1 | 2016 | 130 | 0.110 |
Why?
|
| Genetic Association Studies | 2 | 2017 | 844 | 0.110 |
Why?
|
| Echocardiography, Doppler | 1 | 2015 | 173 | 0.110 |
Why?
|
| Respiration | 1 | 2015 | 125 | 0.110 |
Why?
|
| Pertussis Toxin | 5 | 1994 | 29 | 0.110 |
Why?
|
| Acute Kidney Injury | 1 | 2022 | 686 | 0.110 |
Why?
|
| Heterozygote | 1 | 2016 | 718 | 0.110 |
Why?
|
| Statistics as Topic | 1 | 2015 | 261 | 0.110 |
Why?
|
| Cells, Cultured | 9 | 1999 | 3167 | 0.110 |
Why?
|
| Hibernation | 1 | 1993 | 3 | 0.110 |
Why?
|
| Biomedical Research | 1 | 2020 | 556 | 0.110 |
Why?
|
| Aneurysm | 1 | 2014 | 90 | 0.110 |
Why?
|
| Mass Screening | 1 | 2019 | 832 | 0.110 |
Why?
|
| Tibial Fractures | 1 | 2014 | 63 | 0.110 |
Why?
|
| Tachycardia, Ventricular | 1 | 2016 | 207 | 0.110 |
Why?
|
| Pulmonary Artery | 2 | 2016 | 449 | 0.110 |
Why?
|
| Primary Health Care | 1 | 2000 | 795 | 0.100 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 838 | 0.100 |
Why?
|
| Internship and Residency | 2 | 2017 | 1250 | 0.100 |
Why?
|
| Cardiac Volume | 1 | 2013 | 18 | 0.100 |
Why?
|
| Lung Diseases | 1 | 2017 | 401 | 0.100 |
Why?
|
| Aged | 7 | 2025 | 21717 | 0.100 |
Why?
|
| Heart Arrest | 1 | 2017 | 376 | 0.100 |
Why?
|
| Comorbidity | 2 | 2016 | 1613 | 0.100 |
Why?
|
| Dogs | 3 | 2004 | 800 | 0.100 |
Why?
|
| Lung Transplantation | 1 | 2017 | 335 | 0.100 |
Why?
|
| Protozoan Proteins | 1 | 1994 | 135 | 0.100 |
Why?
|
| Nitric Oxide | 1 | 2016 | 490 | 0.100 |
Why?
|
| Kinetics | 7 | 2001 | 1354 | 0.100 |
Why?
|
| Education, Medical, Continuing | 1 | 2013 | 145 | 0.100 |
Why?
|
| Adenosine Diphosphate Ribose | 5 | 1993 | 13 | 0.100 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 2 | 2020 | 57 | 0.090 |
Why?
|
| Emergency Service, Hospital | 1 | 2000 | 1147 | 0.090 |
Why?
|
| Survival Rate | 4 | 2019 | 2207 | 0.090 |
Why?
|
| Inositol Phosphates | 2 | 2001 | 13 | 0.090 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 3738 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 1993 | 292 | 0.090 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 604 | 0.090 |
Why?
|
| Time-to-Treatment | 1 | 2013 | 202 | 0.090 |
Why?
|
| Adenylate Cyclase Toxin | 4 | 1994 | 6 | 0.090 |
Why?
|
| Hospital Costs | 1 | 2013 | 187 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2024 | 428 | 0.090 |
Why?
|
| Perinatal Mortality | 2 | 2020 | 44 | 0.090 |
Why?
|
| Microfilament Proteins | 2 | 2021 | 290 | 0.090 |
Why?
|
| Peptides | 1 | 1994 | 861 | 0.090 |
Why?
|
| Socioeconomic Factors | 1 | 2013 | 919 | 0.080 |
Why?
|
| Exome | 2 | 2025 | 1067 | 0.080 |
Why?
|
| Age of Onset | 2 | 2024 | 635 | 0.080 |
Why?
|
| Odds Ratio | 1 | 2013 | 1337 | 0.080 |
Why?
|
| Cardiovascular Diseases | 2 | 2019 | 2082 | 0.080 |
Why?
|
| Organ Size | 2 | 2016 | 466 | 0.080 |
Why?
|
| Propranolol | 2 | 2022 | 130 | 0.080 |
Why?
|
| Wounds and Injuries | 1 | 2013 | 399 | 0.080 |
Why?
|
| Observer Variation | 2 | 2023 | 312 | 0.080 |
Why?
|
| Congenital Abnormalities | 2 | 2024 | 290 | 0.080 |
Why?
|
| Osteoporosis, Postmenopausal | 1 | 2008 | 31 | 0.070 |
Why?
|
| Progestins | 1 | 2008 | 53 | 0.070 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2008 | 50 | 0.070 |
Why?
|
| Quality of Life | 2 | 2020 | 2132 | 0.070 |
Why?
|
| Heart Failure | 1 | 2022 | 2416 | 0.070 |
Why?
|
| Genome-Wide Association Study | 1 | 2016 | 1872 | 0.070 |
Why?
|
| Guanylyl Imidodiphosphate | 5 | 1994 | 8 | 0.070 |
Why?
|
| Calmodulin | 2 | 2000 | 224 | 0.070 |
Why?
|
| Edetic Acid | 1 | 1987 | 25 | 0.070 |
Why?
|
| Umbilical Veins | 3 | 1996 | 73 | 0.070 |
Why?
|
| Mitosporic Fungi | 2 | 2000 | 9 | 0.070 |
Why?
|
| Research Design | 2 | 2024 | 754 | 0.070 |
Why?
|
| Adenosine | 3 | 2001 | 139 | 0.070 |
Why?
|
| Europe | 2 | 2020 | 384 | 0.070 |
Why?
|
| Brain | 2 | 2018 | 3217 | 0.070 |
Why?
|
| Muscles | 1 | 1987 | 307 | 0.070 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 3 | 1999 | 29 | 0.070 |
Why?
|
| Body Mass Index | 1 | 2013 | 1709 | 0.070 |
Why?
|
| Mice | 11 | 2014 | 18883 | 0.060 |
Why?
|
| Isoproterenol | 6 | 1994 | 109 | 0.060 |
Why?
|
| Drainage | 2 | 2018 | 265 | 0.060 |
Why?
|
| Estrogens | 1 | 2008 | 521 | 0.060 |
Why?
|
| Bone Density | 1 | 2008 | 371 | 0.060 |
Why?
|
| Rats | 7 | 2000 | 3879 | 0.060 |
Why?
|
| Health Services Research | 2 | 2013 | 191 | 0.060 |
Why?
|
| Infant, Premature, Diseases | 2 | 2020 | 255 | 0.060 |
Why?
|
| Fibrillin-2 | 1 | 2024 | 4 | 0.060 |
Why?
|
| Cardiac Myosins | 1 | 2024 | 11 | 0.060 |
Why?
|
| Adenosine Diphosphate | 3 | 2001 | 55 | 0.060 |
Why?
|
| Adipokines | 1 | 2025 | 72 | 0.060 |
Why?
|
| Salmonella Infections, Animal | 1 | 2004 | 6 | 0.060 |
Why?
|
| Chickenpox Vaccine | 1 | 2004 | 14 | 0.060 |
Why?
|
| Measles Vaccine | 1 | 2004 | 13 | 0.060 |
Why?
|
| Electrocardiography, Ambulatory | 1 | 2024 | 63 | 0.060 |
Why?
|
| Viral Hepatitis Vaccines | 1 | 2004 | 19 | 0.060 |
Why?
|
| Animals, Domestic | 1 | 2004 | 33 | 0.060 |
Why?
|
| Bites and Stings | 1 | 2004 | 28 | 0.060 |
Why?
|
| Myosin Heavy Chains | 1 | 2024 | 78 | 0.060 |
Why?
|
| Clubfoot | 1 | 2024 | 21 | 0.060 |
Why?
|
| Hyperbilirubinemia | 1 | 2004 | 42 | 0.060 |
Why?
|
| Hospitals, General | 1 | 2024 | 24 | 0.060 |
Why?
|
| Cryptorchidism | 1 | 2024 | 38 | 0.060 |
Why?
|
| Focal Adhesion Kinase 1 | 1 | 2014 | 26 | 0.060 |
Why?
|
| Ionophores | 2 | 1998 | 12 | 0.060 |
Why?
|
| Massachusetts | 1 | 2024 | 131 | 0.050 |
Why?
|
| Curriculum | 3 | 2017 | 777 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 2 | 2013 | 567 | 0.050 |
Why?
|
| Rotavirus Vaccines | 1 | 2004 | 73 | 0.050 |
Why?
|
| Facies | 1 | 2024 | 154 | 0.050 |
Why?
|
| Whooping Cough | 1 | 2004 | 60 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 1 | 1 | 2014 | 64 | 0.050 |
Why?
|
| Bilirubin | 1 | 2004 | 131 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 736 | 0.050 |
Why?
|
| Hand Deformities, Congenital | 1 | 2024 | 95 | 0.050 |
Why?
|
| Genomics | 2 | 2025 | 1676 | 0.050 |
Why?
|
| Patient Readmission | 2 | 2020 | 412 | 0.050 |
Why?
|
| Immune Sera | 2 | 1994 | 95 | 0.050 |
Why?
|
| Anti-Bacterial Agents | 1 | 1994 | 2515 | 0.050 |
Why?
|
| Growth Disorders | 1 | 2024 | 221 | 0.050 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 324 | 0.050 |
Why?
|
| Fellowships and Scholarships | 2 | 2017 | 313 | 0.050 |
Why?
|
| Biological Variation, Population | 1 | 2022 | 25 | 0.050 |
Why?
|
| Cytosol | 2 | 1999 | 168 | 0.050 |
Why?
|
| Transforming Growth Factor beta | 1 | 2024 | 486 | 0.050 |
Why?
|
| Acute Disease | 3 | 1996 | 1189 | 0.050 |
Why?
|
| Adenylyl Cyclase Inhibitors | 2 | 1993 | 11 | 0.050 |
Why?
|
| Blotting, Western | 2 | 1994 | 1134 | 0.050 |
Why?
|
| Platelet Activation | 1 | 2001 | 71 | 0.050 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2001 | 64 | 0.050 |
Why?
|
| Tyrosine | 1 | 2001 | 158 | 0.050 |
Why?
|
| Blood Flow Velocity | 2 | 2020 | 467 | 0.050 |
Why?
|
| Women's Health | 1 | 2022 | 150 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 1994 | 2785 | 0.050 |
Why?
|
| Guanosine Triphosphate | 3 | 1993 | 52 | 0.040 |
Why?
|
| Mice, Inbred Strains | 2 | 1994 | 321 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2024 | 584 | 0.040 |
Why?
|
| Geography | 1 | 2021 | 124 | 0.040 |
Why?
|
| Cell Membrane Permeability | 3 | 2000 | 76 | 0.040 |
Why?
|
| Constriction | 1 | 2020 | 50 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 2016 | 1124 | 0.040 |
Why?
|
| Anti-Arrhythmia Agents | 1 | 2022 | 224 | 0.040 |
Why?
|
| In Vitro Techniques | 2 | 1993 | 991 | 0.040 |
Why?
|
| Pneumonia | 1 | 2004 | 342 | 0.040 |
Why?
|
| Indomethacin | 1 | 2020 | 86 | 0.040 |
Why?
|
| Ibuprofen | 1 | 2020 | 43 | 0.040 |
Why?
|
| Binding, Competitive | 3 | 2001 | 194 | 0.040 |
Why?
|
| Adrenergic beta-1 Receptor Antagonists | 1 | 2020 | 15 | 0.040 |
Why?
|
| Molecular Sequence Data | 3 | 1994 | 3970 | 0.040 |
Why?
|
| Life Tables | 1 | 2000 | 28 | 0.040 |
Why?
|
| Canada | 1 | 2021 | 343 | 0.040 |
Why?
|
| Saponins | 1 | 2000 | 23 | 0.040 |
Why?
|
| New York City | 1 | 2000 | 63 | 0.040 |
Why?
|
| Holistic Health | 1 | 2020 | 11 | 0.040 |
Why?
|
| Creatinine | 1 | 2022 | 423 | 0.040 |
Why?
|
| Pulmonary Wedge Pressure | 1 | 2020 | 52 | 0.040 |
Why?
|
| Triterpenes | 1 | 2000 | 24 | 0.040 |
Why?
|
| Cell Line | 3 | 2001 | 2837 | 0.040 |
Why?
|
| Social Class | 1 | 2021 | 205 | 0.040 |
Why?
|
| Subcellular Fractions | 1 | 1999 | 99 | 0.040 |
Why?
|
| Prenatal Care | 1 | 2022 | 359 | 0.040 |
Why?
|
| Surveys and Questionnaires | 2 | 2020 | 3987 | 0.040 |
Why?
|
| Prazosin | 2 | 1996 | 7 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 18 | 1 | 1999 | 64 | 0.040 |
Why?
|
| Biopsy | 1 | 2023 | 1304 | 0.040 |
Why?
|
| North America | 1 | 2020 | 260 | 0.040 |
Why?
|
| Influenza Vaccines | 1 | 2004 | 491 | 0.040 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2022 | 266 | 0.040 |
Why?
|
| Radiography | 2 | 2014 | 825 | 0.040 |
Why?
|
| Scintillation Counting | 1 | 1999 | 6 | 0.040 |
Why?
|
| Graft Rejection | 1 | 2023 | 628 | 0.040 |
Why?
|
| Type C Phospholipases | 1 | 1999 | 29 | 0.040 |
Why?
|
| Bradykinin | 2 | 1989 | 49 | 0.040 |
Why?
|
| Baculoviridae | 1 | 1999 | 68 | 0.040 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2000 | 801 | 0.040 |
Why?
|
| Infant Care | 1 | 2019 | 47 | 0.040 |
Why?
|
| Bone Resorption | 1 | 1999 | 53 | 0.040 |
Why?
|
| Anthropometry | 1 | 1999 | 202 | 0.040 |
Why?
|
| Insecta | 1 | 1999 | 67 | 0.040 |
Why?
|
| Infectious Disease Transmission, Vertical | 1 | 2021 | 253 | 0.040 |
Why?
|
| Osteoclasts | 1 | 1999 | 74 | 0.040 |
Why?
|
| Myocytes, Cardiac | 1 | 2014 | 672 | 0.040 |
Why?
|
| Delphi Technique | 1 | 2020 | 244 | 0.040 |
Why?
|
| Parturition | 1 | 2019 | 67 | 0.040 |
Why?
|
| Mitral Valve Stenosis | 1 | 2018 | 36 | 0.040 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2018 | 59 | 0.040 |
Why?
|
| Arterial Pressure | 1 | 2019 | 118 | 0.040 |
Why?
|
| Valinomycin | 1 | 1998 | 1 | 0.040 |
Why?
|
| Nigericin | 1 | 1998 | 3 | 0.040 |
Why?
|
| Thapsigargin | 1 | 1998 | 23 | 0.040 |
Why?
|
| Monensin | 1 | 1998 | 11 | 0.040 |
Why?
|
| Mice, Transgenic | 1 | 2014 | 2527 | 0.040 |
Why?
|
| Biological Transport, Active | 1 | 1998 | 89 | 0.040 |
Why?
|
| Academic Medical Centers | 1 | 2000 | 333 | 0.040 |
Why?
|
| Protein Binding | 2 | 2000 | 1834 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 225 | 0.040 |
Why?
|
| Terpenes | 1 | 1998 | 30 | 0.040 |
Why?
|
| Microsomes | 1 | 1997 | 55 | 0.040 |
Why?
|
| Chromosomes, Human, X | 1 | 2018 | 161 | 0.040 |
Why?
|
| MEDLINE | 1 | 2017 | 20 | 0.040 |
Why?
|
| Birth Weight | 2 | 2015 | 352 | 0.030 |
Why?
|
| Norwood Procedures | 1 | 2019 | 104 | 0.030 |
Why?
|
| Muscle, Smooth | 1 | 2018 | 138 | 0.030 |
Why?
|
| Cerebellum | 2 | 2000 | 462 | 0.030 |
Why?
|
| National Heart, Lung, and Blood Institute (U.S.) | 1 | 2017 | 44 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2019 | 310 | 0.030 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2017 | 2935 | 0.030 |
Why?
|
| Insurance, Health | 1 | 2018 | 144 | 0.030 |
Why?
|
| Inheritance Patterns | 1 | 2017 | 131 | 0.030 |
Why?
|
| Hydrops Fetalis | 1 | 2017 | 77 | 0.030 |
Why?
|
| Medical Records | 1 | 2018 | 194 | 0.030 |
Why?
|
| Intensive Care Units, Neonatal | 1 | 2020 | 327 | 0.030 |
Why?
|
| Microcirculation | 3 | 1996 | 118 | 0.030 |
Why?
|
| Genetic Heterogeneity | 1 | 2017 | 141 | 0.030 |
Why?
|
| Coronary Angiography | 1 | 2019 | 482 | 0.030 |
Why?
|
| Diltiazem | 1 | 1996 | 14 | 0.030 |
Why?
|
| Diseases in Twins | 1 | 2017 | 99 | 0.030 |
Why?
|
| Drosophila | 1 | 2001 | 824 | 0.030 |
Why?
|
| Intellectual Disability | 1 | 2024 | 1076 | 0.030 |
Why?
|
| Adrenergic alpha-Antagonists | 1 | 1996 | 39 | 0.030 |
Why?
|
| Stillbirth | 1 | 2017 | 103 | 0.030 |
Why?
|
| Mental Health | 1 | 2020 | 372 | 0.030 |
Why?
|
| Japan | 1 | 2016 | 156 | 0.030 |
Why?
|
| Australia | 1 | 2016 | 190 | 0.030 |
Why?
|
| Sf9 Cells | 1 | 2016 | 10 | 0.030 |
Why?
|
| Cost of Illness | 1 | 2018 | 275 | 0.030 |
Why?
|
| Allografts | 1 | 2017 | 197 | 0.030 |
Why?
|
| Biomechanical Phenomena | 1 | 2017 | 263 | 0.030 |
Why?
|
| Nonlinear Dynamics | 1 | 2016 | 53 | 0.030 |
Why?
|
| Colforsin | 3 | 1993 | 51 | 0.030 |
Why?
|
| Inositol 1,4,5-Trisphosphate | 3 | 2001 | 13 | 0.030 |
Why?
|
| Referral and Consultation | 1 | 2000 | 571 | 0.030 |
Why?
|
| Heart Septal Defects | 1 | 2016 | 41 | 0.030 |
Why?
|
| Birthing Centers | 1 | 2015 | 10 | 0.030 |
Why?
|
| Causality | 1 | 2016 | 94 | 0.030 |
Why?
|
| Abortion, Eugenic | 1 | 2015 | 9 | 0.030 |
Why?
|
| Aorta, Abdominal | 1 | 2016 | 125 | 0.030 |
Why?
|
| Incidental Findings | 1 | 2016 | 128 | 0.030 |
Why?
|
| Logistic Models | 1 | 2020 | 1909 | 0.030 |
Why?
|
| Alleles | 1 | 2020 | 1706 | 0.030 |
Why?
|
| Computed Tomography Angiography | 1 | 2017 | 210 | 0.030 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2017 | 257 | 0.030 |
Why?
|
| Arginine | 1 | 2018 | 349 | 0.030 |
Why?
|
| RNA, Messenger | 2 | 1999 | 2902 | 0.030 |
Why?
|
| Clinical Trials as Topic | 1 | 2020 | 1153 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 1999 | 1735 | 0.030 |
Why?
|
| Sex Distribution | 1 | 2016 | 330 | 0.030 |
Why?
|
| Morbidity | 1 | 2015 | 255 | 0.030 |
Why?
|
| Pericardial Effusion | 1 | 2015 | 71 | 0.030 |
Why?
|
| Age Distribution | 1 | 2016 | 444 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 1996 | 253 | 0.030 |
Why?
|
| Spectrometry, Mass, Fast Atom Bombardment | 1 | 1994 | 2 | 0.030 |
Why?
|
| Postpartum Period | 1 | 2016 | 227 | 0.030 |
Why?
|
| External Fixators | 1 | 2014 | 14 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2018 | 1596 | 0.030 |
Why?
|
| Bone Plates | 1 | 2014 | 26 | 0.030 |
Why?
|
| Conscious Sedation | 1 | 2015 | 62 | 0.030 |
Why?
|
| Precipitin Tests | 1 | 1994 | 158 | 0.030 |
Why?
|
| Health Services Accessibility | 1 | 2000 | 648 | 0.030 |
Why?
|
| Fermentation | 1 | 1994 | 71 | 0.030 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1994 | 39 | 0.030 |
Why?
|
| Peptides, Cyclic | 1 | 1994 | 57 | 0.030 |
Why?
|
| Echinocandins | 1 | 1994 | 44 | 0.030 |
Why?
|
| Dexamethasone | 2 | 1993 | 284 | 0.030 |
Why?
|
| Marmota | 1 | 1993 | 3 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 1999 | 1757 | 0.030 |
Why?
|
| Airway Obstruction | 1 | 2016 | 168 | 0.030 |
Why?
|
| ROC Curve | 1 | 2016 | 615 | 0.030 |
Why?
|
| Health Status Indicators | 1 | 2014 | 129 | 0.030 |
Why?
|
| Fracture Fixation, Internal | 1 | 2014 | 82 | 0.030 |
Why?
|
| Thionucleotides | 2 | 1992 | 23 | 0.030 |
Why?
|
| Linear Models | 1 | 2015 | 722 | 0.030 |
Why?
|
| Helminth Proteins | 1 | 1994 | 103 | 0.030 |
Why?
|
| Hospitals, Pediatric | 1 | 2018 | 789 | 0.030 |
Why?
|
| Molecular Structure | 1 | 1994 | 317 | 0.030 |
Why?
|
| Homeostasis | 1 | 1998 | 748 | 0.030 |
Why?
|
| Cardiovascular Abnormalities | 1 | 2013 | 54 | 0.030 |
Why?
|
| Learning Curve | 1 | 2013 | 57 | 0.030 |
Why?
|
| Child Mortality | 1 | 2013 | 26 | 0.030 |
Why?
|
| Candidiasis | 1 | 1994 | 138 | 0.030 |
Why?
|
| Parents | 1 | 2020 | 1058 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 1996 | 374 | 0.030 |
Why?
|
| Cost Savings | 1 | 2013 | 76 | 0.020 |
Why?
|
| Tretinoin | 1 | 1993 | 118 | 0.020 |
Why?
|
| Norepinephrine | 2 | 1994 | 175 | 0.020 |
Why?
|
| Pulmonary Circulation | 1 | 2013 | 122 | 0.020 |
Why?
|
| Self Efficacy | 1 | 2013 | 205 | 0.020 |
Why?
|
| 3',5'-Cyclic-AMP Phosphodiesterases | 1 | 1992 | 23 | 0.020 |
Why?
|
| Hypothalamus | 1 | 1993 | 219 | 0.020 |
Why?
|
| Cell Hypoxia | 1 | 1992 | 104 | 0.020 |
Why?
|
| Iodocyanopindolol | 1 | 1991 | 3 | 0.020 |
Why?
|
| Pindolol | 1 | 1991 | 8 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 1976 | 0.020 |
Why?
|
| Extracorporeal Membrane Oxygenation | 1 | 2018 | 640 | 0.020 |
Why?
|
| Trypanosoma | 1 | 1991 | 10 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2016 | 1488 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 1993 | 644 | 0.020 |
Why?
|
| Estradiol | 1 | 1993 | 551 | 0.020 |
Why?
|
| Fibroblast Growth Factor 1 | 1 | 1990 | 15 | 0.020 |
Why?
|
| Heart Rate | 1 | 1994 | 601 | 0.020 |
Why?
|
| Mitogens | 1 | 1990 | 32 | 0.020 |
Why?
|
| Heparitin Sulfate | 1 | 1990 | 22 | 0.020 |
Why?
|
| Platelet Adhesiveness | 1 | 1990 | 41 | 0.020 |
Why?
|
| Proteoglycans | 1 | 1990 | 94 | 0.020 |
Why?
|
| Host-Parasite Interactions | 1 | 1990 | 83 | 0.020 |
Why?
|
| Platelet Aggregation | 1 | 1990 | 125 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2013 | 817 | 0.020 |
Why?
|
| Osteosarcoma | 1 | 1993 | 263 | 0.020 |
Why?
|
| Cell Membrane | 2 | 1993 | 486 | 0.020 |
Why?
|
| Critical Care | 1 | 2015 | 689 | 0.020 |
Why?
|
| Advanced Cardiac Life Support | 1 | 2009 | 18 | 0.020 |
Why?
|
| Phlebotomy | 1 | 2009 | 20 | 0.020 |
Why?
|
| Infant, Premature | 1 | 2015 | 859 | 0.020 |
Why?
|
| Boston | 1 | 2009 | 122 | 0.020 |
Why?
|
| Spinal Puncture | 1 | 2009 | 53 | 0.020 |
Why?
|
| Biomarkers | 1 | 2019 | 3422 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 1996 | 1052 | 0.020 |
Why?
|
| Chronic Disease | 2 | 1990 | 1253 | 0.020 |
Why?
|
| Vascular Diseases | 1 | 1990 | 158 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2009 | 114 | 0.020 |
Why?
|
| Calcium Signaling | 2 | 2001 | 255 | 0.020 |
Why?
|
| Femur Neck | 1 | 2008 | 15 | 0.020 |
Why?
|
| Oligomycins | 1 | 1988 | 5 | 0.020 |
Why?
|
| Ionomycin | 1 | 1988 | 19 | 0.020 |
Why?
|
| Gastrointestinal Diseases | 1 | 1992 | 361 | 0.020 |
Why?
|
| Ethers | 1 | 1988 | 7 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 1988 | 66 | 0.020 |
Why?
|
| Ribose | 1 | 1988 | 14 | 0.020 |
Why?
|
| Cations, Divalent | 1 | 1988 | 21 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2008 | 61 | 0.020 |
Why?
|
| Spinal Fractures | 1 | 2008 | 47 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2013 | 999 | 0.020 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2016 | 787 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1987 | 236 | 0.020 |
Why?
|
| Lumbar Vertebrae | 1 | 2008 | 118 | 0.020 |
Why?
|
| Catheterization, Peripheral | 1 | 2009 | 129 | 0.020 |
Why?
|
| Acetylcholine | 1 | 1987 | 87 | 0.020 |
Why?
|
| Angiotensin II | 1 | 1988 | 168 | 0.020 |
Why?
|
| Species Specificity | 1 | 1987 | 571 | 0.020 |
Why?
|
| Disease Models, Animal | 3 | 1996 | 4772 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2017 | 7200 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 2 | 2000 | 1102 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2008 | 1197 | 0.010 |
Why?
|
| Cattle | 2 | 1997 | 588 | 0.010 |
Why?
|
| Radiation Hybrid Mapping | 1 | 2002 | 6 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 83 | 0.010 |
Why?
|
| LIM Domain Proteins | 1 | 2002 | 62 | 0.010 |
Why?
|
| Synteny | 1 | 2002 | 80 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2002 | 71 | 0.010 |
Why?
|
| Thromboxane A2 | 1 | 2001 | 19 | 0.010 |
Why?
|
| Intracellular Fluid | 1 | 2001 | 25 | 0.010 |
Why?
|
| Dimerization | 1 | 2001 | 152 | 0.010 |
Why?
|
| Zebrafish Proteins | 1 | 2002 | 128 | 0.010 |
Why?
|
| Cross-Linking Reagents | 1 | 2001 | 61 | 0.010 |
Why?
|
| Acetates | 1 | 2001 | 79 | 0.010 |
Why?
|
| Oligopeptides | 1 | 2001 | 122 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2001 | 239 | 0.010 |
Why?
|
| Cytoskeletal Proteins | 1 | 2002 | 280 | 0.010 |
Why?
|
| Cricetinae | 1 | 2001 | 398 | 0.010 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 791 | 0.010 |
Why?
|
| Serotonin | 1 | 2001 | 224 | 0.010 |
Why?
|
| Mammals | 1 | 2001 | 277 | 0.010 |
Why?
|
| Carbohydrate Conformation | 1 | 2000 | 16 | 0.010 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2002 | 406 | 0.010 |
Why?
|
| Ligands | 1 | 2001 | 572 | 0.010 |
Why?
|
| Spodoptera | 1 | 1999 | 47 | 0.010 |
Why?
|
| Muscle Proteins | 1 | 2002 | 423 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2001 | 873 | 0.010 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2001 | 283 | 0.010 |
Why?
|
| Animals, Newborn | 2 | 1994 | 1045 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2000 | 170 | 0.010 |
Why?
|
| Binding Sites | 1 | 2001 | 1369 | 0.010 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2000 | 306 | 0.010 |
Why?
|
| Models, Structural | 1 | 1997 | 50 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2002 | 1064 | 0.010 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2000 | 827 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 1996 | 24 | 0.010 |
Why?
|
| Models, Neurological | 1 | 1997 | 223 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 1999 | 1439 | 0.010 |
Why?
|
| Spasm | 1 | 1996 | 52 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2000 | 1702 | 0.010 |
Why?
|
| Antibodies, Monoclonal | 1 | 2001 | 1069 | 0.010 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1994 | 9 | 0.010 |
Why?
|
| Uncoupling Agents | 1 | 1993 | 5 | 0.010 |
Why?
|
| Preoptic Area | 1 | 1993 | 12 | 0.010 |
Why?
|
| Ovariectomy | 1 | 1993 | 188 | 0.010 |
Why?
|
| Sodium Fluoride | 1 | 1993 | 11 | 0.010 |
Why?
|
| Temperature | 1 | 1994 | 330 | 0.010 |
Why?
|
| Hydrogen-Ion Concentration | 1 | 1994 | 470 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1993 | 270 | 0.010 |
Why?
|
| Contraindications | 1 | 1992 | 81 | 0.010 |
Why?
|
| Inulin | 1 | 1992 | 19 | 0.010 |
Why?
|
| Bucladesine | 1 | 1992 | 21 | 0.010 |
Why?
|
| Sorbitol | 1 | 1992 | 9 | 0.010 |
Why?
|
| Receptors, Thrombin | 1 | 1992 | 14 | 0.010 |
Why?
|
| Liver | 1 | 2000 | 1867 | 0.010 |
Why?
|
| Thrombin | 1 | 1992 | 62 | 0.010 |
Why?
|
| Serum Albumin | 1 | 1992 | 118 | 0.010 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1994 | 621 | 0.010 |
Why?
|
| Thromboxane B2 | 1 | 1990 | 21 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 1993 | 1306 | 0.010 |
Why?
|
| Blood Transfusion | 1 | 1992 | 321 | 0.010 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 1990 | 153 | 0.010 |
Why?
|
| Epoprostenol | 1 | 1990 | 71 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 1989 | 122 | 0.010 |
Why?
|
| Receptors, Cell Surface | 1 | 1992 | 494 | 0.010 |
Why?
|
| Nervous System Diseases | 1 | 1992 | 408 | 0.000 |
Why?
|
| Fibrosis | 1 | 1989 | 461 | 0.000 |
Why?
|
| Blood Platelets | 1 | 1990 | 341 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1989 | 1667 | 0.000 |
Why?
|